Free tool
FAERS Monitor: Acthar Gel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 008372 or its brand name (Acthar Gel, Corticotropin). Reports on generic versions are filed under their own applications.
Reports
4,450
Serious
1,711
38% of reports
Hospitalization
534
Death reported
61
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site bruising385
- fatigue381
- product dose omission issue317
- injection site pain301
- headache268
- insomnia255
- condition aggravated198
- weight increased198
- pain191
- drug ineffective180
- blood glucose increased172
- asthenia161
- peripheral swelling154
- injection site pruritus144
- fluid retention140
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 7 |
| 2012 | 24 |
| 2013 | 46 |
| 2014 | 73 |
| 2015 | 65 |
| 2016 | 64 |
| 2017 | 77 |
| 2018 | 104 |
| 2019 | 85 |
| 2020 | 41 |
| 2021 | 43 |
| 2022 | 47 |
| 2023 | 59 |
| 2024 | 63 |
| 2025 | 83 |
| 2026 | 3,566 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,709 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site bruisingSignal | 385 | 22.9 | 20.8 | 8,039 |
| fluid retentionSignal | 140 | 13.0 | 11.1 | 1,544 |
| injection site pruritusSignal | 144 | 10.2 | 8.7 | 1,184 |
| product dose omission issueSignal | 317 | 5.1 | 4.6 | 1,054 |
| peripheral swellingSignal | 154 | 4.7 | 4.0 | 452 |
| injection site painSignal | 301 | 4.6 | 4.2 | 868 |
| insomniaSignal | 255 | 4.5 | 4.0 | 706 |
| blood glucose increasedSignal | 172 | 4.3 | 3.7 | 439 |
| weight increasedSignal | 198 | 4.2 | 3.6 | 481 |
| condition aggravatedSignal | 198 | 3.1 | 2.7 | 280 |
| fatigueSignal | 381 | 2.3 | 2.1 | 294 |
| astheniaSignal | 161 | 2.0 | 1.7 | 84 |
| headacheSignal | 268 | 2.0 | 1.8 | 141 |
| pain | 191 | 1.5 | 1.3 | 29 |
| drug ineffective | 180 | 0.6 | 0.6 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.